|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02607 SH PHARMA
Nominal 
11.510 -0.030 (-0.260%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Turnover | 147,469,729 | 4.151% | 141,592,783 | 139,413,146 | 132,592,157 | 111,707,464 |
| Cost of Sales | (131,209,437) | 3.592% | (126,660,061) | -- | -- | -- |
| Gross Profit | 16,260,293 | 8.890% | 14,932,722 | -- | -- | -- |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (533,920) | -29.590% | (758,298) | (215,493) | (73,375) | (152,852) | |
| Profit / (Loss) on Disposal | 179,700 | 349.402% | 39,986 | 139,310 | 73,746 | 1,427,180 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 48,792 | -87.182% | 380,664 | 365,613 | (65,419) | 377,555 | |
| Profit / (Loss) before Taxation | 5,631,383 | -17.438% | 6,820,821 | 4,822,021 | 4,533,793 | 5,757,963 | |
| Taxation | (1,289,727) | -29.370% | (1,826,037) | (1,224,658) | (1,116,791) | (1,193,744) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (837,209) | 56.219% | (535,919) | (655,452) | (807,179) | (868,613) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,504,447 | -21.405% | 4,458,865 | 2,941,911 | 2,609,822 | 3,695,607 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 694,509 | -7.371% | 749,775 | 705,939 | 773,220 | 648,914 |
| Depreciation & Amortisation | 1,518,858 | 3.678% | 1,464,970 | 1,248,982 | 1,179,235 | 1,193,683 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| EPS (cts) | 95.000 | -20.833% | 120.000 | 79.000 | 71.000 | 113.000 |
| DPS (cts) | 10.000 | -- | 12.000 | 8.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | 10.526% | -- | 10.000% | 10.127% | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 21.127 | -- | 20.250 | 18.898 | 18.189 | 17.674 |
| Remarks: | Real time quote last updated: 09/09/2026 17:53 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,504,447 |
| %Change | -21.405% |
| EPS / (LPS) | RMB 0.950 |
| NBV Per Share (¥) | RMB 21.127 |